Drug Combination Details
| General Information of the Combination (ID: C04513) | |||||
|---|---|---|---|---|---|
| Name | Arsenic trioxide NP Info | + | Ganciclovir Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Nasopharyngeal cancer
[ICD-11: 2B6B]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| In-vivo Model | CNE1 < BX1 > cells (7.5*106 cells/mouse) were trypsinized and mixed with growth factor reduced matrigel and injected subcutaneously on the right flank of each mouse. | |||||
| Experimental
Result(s) |
Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Co-treatment with arsenic trioxide and ganciclovir reduces tumor volume in a murine xenograft model of nasopharyngeal carcinoma. Virol J. 2013 May 16;10:152. | |||
